A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
Financial Summary
| Share Statistics | FEED | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.9 | $334.8 | 1% |
|
| Shares Out (Mil) | 3.3 | 41.7 | 11% |
|
| Institutional Ownership | 99.9% | 77.3% | 96% |
|
| Float (Mil) | 6.1 | 34.7 | 14% |
|
| Beta | 1.56 | 0.86 | 84% |
|
| Avg Daily Volume (000s) | 155 | 266 | 41% |
|
| Price Change (52-week) |
(96.2%) | 60.7% | 2% |
|
| Growth | FEED | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 34.1% | 11.8% | 92% |
|
| Net Income (5yr) | (33.5%) | (5.8%) | 12% |
|
| EPS (5yr) | na | 10.7% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (16.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FEED | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $152 | 3% |
|
| Net Income (TTM) (Mil) | ($20) | ($11) | 24% |
|
| EPS (TTM) | ($26.147) | ($0.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($2) | 18% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $1 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $2 | $304 | 4% |
|
| Valuation | FEED | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.04 | 2.88 | 1% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | FEED | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (12.4%) | 59.1% | 3% |
|
| Net Margin | (923.2%) | (7.7%) | 0% |
|
| ROA | (48.0%) | (13.7%) | 12% |
|
| ROE | (59.5%) | (15.9%) | 14% |
|
| Liabilities to Assets | 19.7% | 44.9% | 12% |
|
| F-Score | 2 | 4 | 7% |
|
ENvue Medical, Inc. did not pass any screens on 7/30/2026.
